Sandoz, the generics arm of Swiss drug maker Novartis AG, has decided to shutter a second research and development (R&D) centre in India in under 12 months. This time it is the formulations or finished dosage forms R&D unit located in Kalwe, near Mumbai, that is facing closure affecting 147 employees. Novartis India confirmed the … Continue reading Scoop : Sandoz shutters India formulations R&D
Tag: India R&D
It takes a village : What Ranbaxy’s Synriam tells us
Synriam, Ranbaxy's new anti-malarial drug combination, is the first new drug R&D project by an Indian generics company that's yielded a marketable drug. That's big in itself as various media reports have acknowledged. To me, its key value lies not so much in its "firstness." Its value is even greater as a case study - … Continue reading It takes a village : What Ranbaxy’s Synriam tells us
Apothecurry 